DelveInsight has launched a new report on “Non-Muscle Invasive Bladder Cancer Pipeline”
Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.
Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight
Non-Muscle Invasive Bladder Cancer Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities
Non-Muscle Invasive Bladder Cancer Pipeline
The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. The major key players include Viventia Bio/Sesen Bio (Vicinium), FKD Therapies Oy/Ferring Pharmaceuticals (Adstiladrin), CG Oncology (CG0070), ImmunityBio/Altor Biosciences (N-803 (ALT-803)), Theralase (TLD-1433), Merck (Keytruda) and others that hold the potential to create a significant positive shift in NMIBC in the market size.
Marketed drugs included in the report
Emerging drugs included in the report
Non-Muscle Invasive Bladder Cancer Emerging Therapy
Keytruda is developed by Merck and marketed in the United States which is a humanized monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response. The drug is also in trial for Europe and Japan.
Non-Muscle Invasive Bladder Cancer Emerging Therapy Assessment
CG Oncology is developing CG0070 which has completed phase II clinical developmental trial and is planning to initiate a phase III trial for the patients with NMIBC. CG0070, a selectively replicative oncolytic immunotherapy based on a modified adenovirus type 5 backbone that contains a cancer-selective promoter and a GM-CSF transgene, destroys bladder tumor cells through their defective Rb pathway. CG0070 was designed to work in two complementary ways. First, it replicates inside the tumor’s cells with dysfunctional Rb pathways, causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response that involves the body’s white blood cells.
Non-Muscle Invasive Bladder Cancer Companies
Non-Muscle Invasive Bladder Cancer Symptoms
Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:
Non-Muscle Invasive Bladder Cancer Report Highlights
Table of content
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/